Sacubitril/Valsartan is indicated for the treatment of heart failure (NYHA class II-IV) in patients with systolic dysfunction. The product has been shown to reduce the rate of cardiovascular death and heart failure hospitalization compared to angiotensin converting enzyme (ACE) inhibitor therapy.
Out-licensing: offered for all international market
* Product availability is subject to patent restrictions in countries where applicable patents are in effect
